Stealth Viruses (Part II)













Continued from Part I

Clinical Conditions Associated with Stealth Virus Infections

Stealth-adapted viruses have been recovered from the blood, cerebrospinal fluid, urine, throat swabs, breast milk, brain biopsies and tumor samples from patients with various neurological, psychiatric, auto-immune, allergic and neoplastic diseases. Examples of neurological illnesses are autism, attention deficit and behavioral disorders in children; depression, schizophrenia, amyotrophic lateral sclerosis, multiple sclerosis, chronic fatigue and fibromyalgia in adults; and neurodegenerative illnesses in the elderly. It is now known that stealth viruses can infect many organs, but that the brain is especially prone to manifest the effects of even limited localized cellular damage. The varying manifestations of a stealth virus encephalopathy are probably heavily influenced by the timing of infection, regions of the brain that are mostly involved, genetic predisposition to particular symptoms and the additive pathology of any superimposed auto-immune component triggered by the viral induced cellular damage.

Cancer can now be added to the list of potential stealth virus-associated diseases. Positive stealth virus cultures have been seen in virtually all of the multiple myeloma patients tested, and in several patients presenting with other types of tumors. A previous history of a fatiguing illness and clinical indications of impairments in normal brain functions are suggestive of an underlying stealth-adapted virus infection in a cancer patient. It will be interesting to determine the effect of stealth-virus suppressive therapy in such patients.

An indication of the probable prevalence of infection among apparently healthy individuals has come from studies conducted on student blood donors attending a college campus. Slightly less than 10% of the units tested gave a positive result. As a requirement of the study, it was not possible to determine the actual health status of these students, and no efforts were made to follow the recipients who received these units. Even if culture-positive individuals are asymptomatic, the potential of stealth-adapted viruses to "capture, amplify and mutate" various additional genes of viral, cellular and bacterial origins, should raise some Public Health concerns.
Role of Other Infectious Agents in Chronic Illnesses

Much of the debate over a potential infectious cause for many of the illnesses that are increasingly being seen within our society has centered upon conventional microorganisms. Patient support groups and their affiliating clinicians have championed alternative explanations for these illnesses. Human herpes virus-6 (HHV-6), human herpes virus-8 (HHV-8), enteroviruses and parvo-viruses feature among the viral causes for these illnesses, while Borrelia burgdoferi, Mycoplasma incognitus and Ehlichiosis are being promoted as the bacterial causes for a wide spectrum of illnesses. As is the case for HHV-6 in CFS, HHV-8 in multiple myeloma, enterovirus in ALS and Borrelia in chronic Lyme disease, when looked at critically, the actual findings are generally inconsistent with a true etiological relationship. None of these negative studies exclude the role atypically structured microorganisms; indeed, if anything they strongly support their presence. As alluded to above, stealth-adapted viruses can easily be mistaken in diagnostic tests for conventional viral and bacterial pathogens.

Additional complex associations between stealth-adapted viruses and conventional microorganisms may exist. For example, the lipid-laden cells infected with a stealth virus appear especially favorable to the growth of intracellular bacteria, including Borrelia, the causative agent of Lyme disease. CCID has demonstrated positive stealth virus cultures in blood samples from over 90% of patients referred with a diagnosis of chronic Lyme disease. Whether the patients are actually infected with Borrelia remains unproven, but if so, their growth may be dependent upon an accompanying stealth virus infection. Synergistic growth patterns between stealth-adapted viruses and the viruses present in several live viral vaccine preparations, have also been observed. The potential role of stealth virus encoded chemokine receptors in the evolution and the present day expression of HIV, is also under consideration.

Clinical Approach to the Diagnosis and Therapy of Stealth Adapted Virus Infections (SAVI)

Diagnosis: A major challenge in providing medical care for stealth virus infected patients is the multiple and diverse clinical manifestations of the patients' illnesses. Individual patients do not fit comfortably into a single medical discipline, whether it is psychiatry, neurology, rheumatology, endocrinology, hematology, or any other. Imprecise diagnostic labels, such as CFS, fibromyalgia, depression, attention deficit, etc., and even the better defined diagnostic labels, such as schizophrenia, autism, ALS, multiple sclerosis, Alzheimer's disease, etc., tend to obscure the complex multi-system nature of the patients' illnesses. Another difficulty is quantitating the severity of disease processes that can vary widely over time, and can be influenced by such non-specific factors as stress, environmental exposures to chemicals, placebo effects, etc.

Disordered brain function can be anticipated in many stealth virus infected patients. This can be documented using a detailed neurological examination, with a focus on what are sometimes referred to as "soft" neurological signs. Ancillary, although expensive, tests such as SPECT scans, quantitative EEG and formal neurocognitive evaluations, can help substantiate a diagnosis of stealth-adapted virus infection with encephalopathy. Additional syndrome names can be applied depending on clinical and laboratory findings. Tabulation of symptoms using a detailed questionnaire can be helpful in identifying clinical problems and in assessing therapy related improvements.

Therapy: Until the existence of stealth viruses is accepted by Public Health authorities, there will be no approved standard of care in providing anti-viral treatments. Several suggestions can be made, however, from what is currently known about the prototype SCMV-derived stealth virus. Whether these suggestions are relevant to atypical viruses cultured from other patients remains to be tested. CCID is now reaching out to clinicians involved with the care of stealth virus infected patients for assistance with these clinical trials.

Basically, it seems appropriate to undertake efforts to suppress stealth virus activation and at the same time to support cellular metabolism, especially mitochondria function. The remarkable expansion of chemokine and chemokine -receptor related genes within the prototype SCMV-derived stealth-adapted virus supports the potential use of agents that can down regulate chemokine pathways. Fortunately, many of the widely used herbal and generally non-toxic allopathic medicines are known to interfere with chemokine signaling. It is probably more than a coincidence that many of the compounds have also been reported to benefit at least a proportion of patients with CFS and related illnesses. Ideally, patients receiving these relatively simple therapies would be retested for stealth virus activity. If there were no apparent reduction in stealth virus activity, and if the patient remained symptomatic, one could more easily justify the use of potentially more toxic allopathic medicines, including known anti herpes viral agents.

For patients with major neurological, psychiatric, autoimmune or malignant diseases, the stealth virus associated treatments will simply be an aside to the accepted standard care of the patient's underlying illness. Once sufficient supportive data are collected, it may be possible to proceed directly with anti-stealth virus therapy as the primary treatment for these severe disorders.


© Copyright 2001 by W. John Martin, M.D., Ph.D., USA



Share this...
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInPin on PinterestShare on TumblrEmail this to someone








Comments

One Response to “Stealth Viruses (Part II)”

  1. Stealth Viruses (Part I) | Healing Base on December 9th, 2011 15:04

    […] Continued in Part II […]

Share your thoughts...




XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>


  •  
,